Absence of HBV reactivation in patients with resolved HBV infection following DAA therapy for hepatitis C : a 1-year follow-up study
- Background: Patients with chronic hepatitis C virus (HCV) infection and active or previous hepatitis B virus (HBV) are at risk of HBV reactivation (HBV-R) during direct-acting antiviral (DAA) therapy. Recent reports suggest that HBV-R may even occur several months after completion of DAA therapy. The aim of this study was to assess the risk of HBV-R in patients with resolved HBV after successful DAA therapy during long-term follow-up (FU). Methods: Among 848 patients treated for chronic HCV, all patients with resolved HBV and long-term FU data were eligible for inclusion. Patients were HBV DNA/hepatitis B surface antigen (HBsAg)–negative at the end of therapy (EOT) and were followed for up to 52 weeks thereafter. Patients underwent regular alanine transaminase (ALT) testing, and additional HBV DNA/HBsAg testing was performed at FU week 12, end of FU, and in case of an ALT increase above the upper limit of normal (>ULN). Results: A total of 108 patients were followed up for a mean (range) of 41.5 (24–52) weeks after EOT. None of the patients experienced reverse HBsAg seroconversion or reappearance of HBV DNA. One patient received a liver transplantation; 1 patient was diagnosed with de novo hepatocellular carcinoma, and 2 patients died. Eighteen patients (16.7%) had increased ALT levels (grade 0/1). Of those, the majority were male (72.2%) and significantly more patients had cirrhosis (66.7% vs 36.2%, P = .015) or received ribavirin as part of their treatment regimen (86.7% vs 46.8%, P = .041). None of these were associated with HBV-R. Conclusions: Our results indicate that the risk of HBV-R in patients with resolved HBV treated with DAAs for HCV is low during long-term follow-up.
Verfasserangaben: | Marcus Maximilian MückeORCiDGND, Victoria Therese MückeORCiDGND, Kai-Henrik PeifferORCiDGND, Christoph SarrazinGND, Stefan ZeuzemORCiDGND, Annemarie BergerGND, Johannes VermehrenGND |
---|---|
URN: | urn:nbn:de:hebis:30:3-488603 |
DOI: | https://doi.org/10.1093/ofid/ofy340 |
ISSN: | 2328-8957 |
Pubmed-Id: | https://pubmed.ncbi.nlm.nih.gov/30648130 |
Titel des übergeordneten Werkes (Englisch): | Open Forum Infectious Diseases |
Verlag: | Oxford University Press |
Verlagsort: | Oxford |
Dokumentart: | Wissenschaftlicher Artikel |
Sprache: | Englisch |
Jahr der Fertigstellung: | 2018 |
Datum der Erstveröffentlichung: | 15.12.2018 |
Veröffentlichende Institution: | Universitätsbibliothek Johann Christian Senckenberg |
Datum der Freischaltung: | 07.02.2019 |
Freies Schlagwort / Tag: | HBV reactivation; HCV treatment; direct-acting antivirals; hepatitis B virus; hepatitis C virus; long-term follow-up |
Jahrgang: | 6 |
Ausgabe / Heft: | 1, ofy340 |
Seitenzahl: | 5 |
Erste Seite: | 1 |
Letzte Seite: | 5 |
Bemerkung: | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
HeBIS-PPN: | 446489549 |
Institute: | Medizin / Medizin |
DDC-Klassifikation: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Sammlungen: | Universitätspublikationen |
Open-Access-Publikationsfonds: | Medizin |
Lizenz (Englisch): | Creative Commons - Namensnennung-Nicht kommerziell 4.0 |